SMA patients protest inconsistent reimbursement standards for Spinraza

Korea Biomedical Review

19 May 2023 - Spinal muscular atrophy patients taking Spinraza (nusinersen sodium) are protesting against the Health Insurance Review and Assessment (HIRA), claiming its review of reimbursement standards is inconsistent.

A task force comprised of young spinal muscular atrophy patients maintained Wednesday that an increasing number of patients experience difficulties as they fail to receive insurance benefits without clear reasons, although they don’t meet the criteria for discontinuing reimbursement announced by HIRA.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder